FOX CHASE CANCER CENTER
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1904-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.foxchase.org
Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis
- Conditions
- Parapsoriasis
- First Posted Date
- 2006-05-05
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00322296
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00321100
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2006-04-18
- Last Posted Date
- 2010-09-23
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT00315185
- Locations
- 🇺🇸
Consultants in Medical Oncology & Hematology Inc., Drexel Hill, Pennsylvania, United States
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
- Conditions
- Metastatic CancerUnspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 720
- Registration Number
- NCT00244868
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸MBCCOP - Meharry Medical College - Nashville, Nashville, Tennessee, United States
🇺🇸Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
- Conditions
- Head and Neck CancerPrecancerous Condition
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00101335
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
- Conditions
- Malignant Mesothelioma
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00003263
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Office of S. Terry Kraus, Marrero, Louisiana, United States
🇺🇸Virginia Oncology Associates, Newport News, Virginia, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00003957
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00087360
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-07-08
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00003109
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder
- Conditions
- Bladder Cancer
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00084578